APHINITY | AACR Cancer Research | Frontier Science Scotland

TITLE OF PUBLICATION

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial

Authors

Richard D.Gelber; Xin V.Wang; Bernard F.Cole; David Cameron; Fatima Cardoso; Vivianne Tjan-Heijnen; Ian Krop; Sherene Loi; Roberto Salgado; Astrid Kiermaier; Elizabeth Frank; Debora Fumagalli; Carmela Caballero; Evandro de Azambuja; Marion Procter; Emma Clark; Eleonora Restuccia; Sarah Heeson; Jose Bines; Sibylle Loiblt; Martine Piccart-Gebhart on behalf of the APHINITY Steering Committee and Investigators

PUBLICATION REFERENCES

CANCER RESEARCH | Volume 82 | Issue 4 | Page(s) Supplement | Publication Year 2022

ALEXANDRA | Journal of the American Medical Association (JAMA)

Feb 3, 2025

The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

Cardiac Safety in the APHINITY trial

Jan 30, 2023

ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.

NeoALTTO: European Journal of Cancer (EJC)

Jan 16, 2023

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Overall survival in the OlympiA trial

Dec 1, 2022

OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo

APHINITY | Annals of Oncology

Sep 1, 2022

Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

May 9, 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer